REQUEST A DEMO
Total
USD $0.00
Search more companies

Protia Inc. (South Korea)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Protia Inc. Profile Updated: June 19, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

The Company is a company mainly engaged in the production and sale of diagnostic kits. Major products include allergy diagnostic kits, human immunoglobulin G and pregnancy diagnostic kits, among others. In addition, the Company is engaged in provision of protein related analysis services. The Company was founded on March 22, 2000 and its shares are listed on KOREA NEW EXCHANGE(KONEX) on December 19, 2018.

Headquarters
Yangcheon-Ro 401, Gangseo Hangang Xi Tower A-Dong 702, Gangseo-Gu, Seoul Metropolitan Government
Seoul; Seoul;

Contact Details: Purchase the Protia Inc. report to view the information.

Website: http://www.proteometech.com

Basic Information
Total Employees:
Purchase the Protia Inc. report to view the information.
Outstanding Shares:
Purchase the Protia Inc. report to view the information.
Registered Capital:
Purchase the Protia Inc. report to view the information.
Financial Auditors:
Purchase the Protia Inc. report to view the information.
Incorporation Date:
March 22, 2000
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Ownership Details
Purchase this report to view the information.
35.4%
Purchase this report to view the information.
13.8%
Purchase this report to view the information.
9.6%
Subsidiaries
(주)프로테옴텍
Company Performance
Financial values in the chart are available after Protia Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
41.52%
Total operating revenue
41.47%
Operating profit (EBIT)
208.67%
EBITDA
169.07%
Net Profit (Loss) for the Period
38.64%
Total assets
13.25%
Total equity
11.75%
Operating Profit Margin (ROS)
10.53%
Net Profit Margin
-0.47%
Return on Equity (ROE)
1.05%
Debt to Equity Ratio
0.22%
Quick Ratio
-2.09%
Cash Ratio
0.7%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?